E2F1 and hepatocellular carcinoma: HCC patients with the ES-like subtype were more sensitive to the E2F1 inhibitor HLM6474, while HCC patients with the LP-like subtype were more sensitive to the SMAD3 inhibitor SIS3, indicating that targeting specific oncofetal drivers may promote drug selectivity and eliminate tumorigenicity effectively [34].